Introduction of hAPOE3Ch into APP/PS1 mice (with and without injection of human AD-tau) resulted in decreased plaque load and AD-tau seeding and spreading, alongside increased microglial reactivity around plaques [41]. The gene discussed is MAPT; the disease is Alzheimer disease.